This Cancer Drug War Is Just Getting Started
The FDA approves Bristol-Myers Squibb's Opdivo, pitting it against Merck's Keytruda that was approved earlier this year.
The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie)
Gilead Sciences Sovaldi was a superstar in 2014, helping Gilead to nearly a 40% year-to-date return. However, one hepatitis C drug developer has delivered 700% better returns to shareholders this year!
3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015
Three Motley Fool analysts tell us which emerging biotechnology stocks they're watching in 2015.